Related Experiment Videos
Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease
1Department of Cardiology and Pneumology, University Hospital Benjamin Franklin, Free University, Berlin, Germany.
Insights
Optimizing oral anticoagulation intensity is key to balancing antithrombotic effects and bleeding risks. Achieving the target International Normalized Ratio (INR) through regular monitoring, like self-testing, improves patient outcomes in long-term therapy.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Management
Background:
- Oral anticoagulation therapy's effectiveness and bleeding risks are directly tied to treatment intensity.
- Determining the optimal intensity involves balancing thromboembolic event prevention with bleeding complication reduction.
- Patient-specific factors, including cardiac morphology and prosthetic device thrombogenicity, influence optimal anticoagulation targets.
Purpose of the Study:
- To define the optimal intensity of oral anticoagulation therapy for individual patients.
- To explore factors influencing the target International Normalized Ratio (INR) in native valve disease and prosthetic devices.
- To highlight the benefits of INR self-testing for improving patient prognosis and maintaining therapeutic INR ranges.
Main Methods:
- Analysis of the correlation between treatment intensity and antithrombotic/bleeding complication rates.
- Consideration of cardiac morphology, pathophysiology (e.g., atrial fibrillation, ventricular function), and valve prosthesis thrombogenicity.
- Evaluation of INR self-testing as a method for precise therapeutic range maintenance.
Main Results:
- The optimal INR target minimizes the combined incidence of thromboembolic and bleeding complications.
- Cardiac and device-specific factors necessitate individualized INR target adjustments.
- INR self-testing significantly enhances patient prognosis by ensuring more precise adherence to the target INR range.
Conclusions:
- Individualized INR targets are crucial for optimizing oral anticoagulation therapy.
- Understanding patient-specific risk factors, including cardiac status and prosthetic type, is essential.
- Self-monitoring of INR, with typically 1-2 weekly measurements for phenprocoumon, enables stable anticoagulation and improved outcomes.
Abstract:
The antithrombotic effect of oral anticoagulation therapy and the incidence of anticoagulant-related bleeding complications are both closely correlated with the intensity of treatment. The optimal intensity of oral anticoagulation for an individual patient is the target INR that results in the lowest incidence of thromboembolic plus bleeding complications. For patients with native valve lesions, one must consider the cardiac morphology and pathophysiology, for example, the etiology of the disease, left atrial diameters, loss of active atrial contraction (atrial fibrillation), left ventricular pump function, and left ventricular diameters, to determine an optimal INR target. In patients with prosthetic devices, the "thrombogenicity" of the heart valve prosthesis is an additional risk factor for intracardiac thrombus formation and thromboembolic episodes. This "thrombogenicity" may vary significantly from device to device. INR self-testing improves the overall prognosis of patients on lifelong oral anticoagulation therapy because patients remain more precisely within that target therapeutic INR range. For most patients under phenprocoumon, one to two INR measurements per week are a sufficient frequency to provide a stable intensity of anticoagulation.